Eravacycline
Based on 30 publication(s) in Google Scholar
Eravacycline is a potent and broad-spectrum antibacterial agent.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1207283-85-9
- Formule: C27H31FN4O8
- Masse moléculaire:558.56
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Eravacycline
More- Nat Microbiol. 2023 Mar;8(3):410-423. [Abstract]
- Biomaterials. 2024 Sep 11:314:122815. [Abstract]
- Nat Struct Mol Biol. 2023 Sep;30(9):1380-1392. [Abstract]
- Pharmaceutics. 2021 Dec 5;13(12):2085. [Abstract]
- Virulence. 2022 Dec;13(1):77-88. [Abstract]
- J Clin Microbiol. 2020 Jan 28;58(2):e01603-19. [Abstract]
- mBio. 2021 Jun 29;12(3):e0103121. [Abstract]
- Antibiotics (Basel). 2022 Sep 23;11(10):1298. [Abstract]
- Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0112023. [Abstract]
- Antimicrob Agents Chemother. 2021 May 18;65(6):e00203-21. [Abstract]
- Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19. [Abstract]
- Ann Lab Med. 2021 May 1;41(3):293-301. [Abstract]
- Microbiol Spectr. 2025 Oct 16:e0160325. [Abstract]
- ACS Infect Dis. 2024 Dec 13;10(12):4127-4136. [Abstract]
- Microbiol Spectr. 2023 Jun 15;11(3):e0071823. [Abstract]
- Microbiol Spectr. 2023 Feb 14;11(1):e0323822. [Abstract]
- J Antimicrob Chemother. 2021 Jul 15;76(8):2071-2078. [Abstract]
- J Antimicrob Chemother. 2021 Feb 11;76(3):653-658. [Abstract]
- Microb Pathog. 2020 Dec;149:104502. [Abstract]
- Pathology. 2026 Feb 6:S0031-3025(26)00393-4. [Abstract]
- Infect Drug Resist. 2023 Sep 8:16:6005-6015. [Abstract]
- Infect Drug Resist. 2023 Apr 17:16:2271-2279. [Abstract]
- J Antibiot (Tokyo). 2026 May 27. [Abstract]
- J Antibiot (Tokyo). 2025 May;78(6):370-379. [Abstract]
- J Antibiot (Tokyo). 2022 Sep;75(9):498-508. [Abstract]
- J Antibiot (Tokyo). 2019 Aug;72(8):600-604. [Abstract]
- Clin Exp Pharmacol Physiol. 2023 Jul;50(7):604-609. [Abstract]
- Diagn Micr Infec Dis. 2020 Nov;98(3):115129. [Abstract]
- Cureus. 2024 Dec 1;16(12):e74917. [Abstract]
- Research Square Preprint. 2022 Feb.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
IF
-
Bio/Physico-chemical Assay
-
ELISA
Voir tous les produits spécifiques à Isoform Beta-lactamase
MoreVoir tous les produits spécifiques à Isoform Antibiotic
More
Activité biologique
|
Tetracycline |
Eravacycline is potent antibiotic against A. baumannii, including isolates that are resistant to sulbactam, imipenem/meropenem, levofloxacin, and amikacin/tobramycin. Eravacycline shows greater activity than the comparators of the tetracycline class, levofloxacin, amikacin, tobramycin, and colistin. The eravacycline MIC50/90 values are 0.5/1 mg/L[1]. Eravacycline shows inhibitory effects on six E. coli with MICs ranging from 0.125 to 0.25 mg/L[2]. Eravacycline dihydrochloride is a synthetic antibiotic, with inhibits bacterial protein synthesis through binding to the 30S ribosomal subunit. Eravacycline displays broad spectrum activity against gram-negative bacteria in the panel except P. aeruginosa, as well as excellent activity against major gram-positive pathogens, including methicillin-resistant S. aureus. Eravacycline also displays potent ribosomal inhibition[3]. Eravacycline shows potent broad-spectrum activity against 90% of the isolates (MIC90) in each panel at concentrations ranging from ≤0.008 to 2 μg/mL for all species panels except those of Pseudomonas aeruginosa and Burkholderia cenocepacia (MIC90 values of 32 μg/mL for both organisms). Eravacycline is active against multidrug-resistant bacteria, including those expressing extended-spectrum β-lactamases and mechanisms conferring resistance to other classes of antibiotics, including carbapenem resistance[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1207283-85-9
-
Appearance Solid
-
Masse moléculaire 558.56
-
Formule C27H31FN4O8
-
Color Light yellow to yellow
-
SMILES
O=C(NC(C(O)=C1C2=O)=CC(F)=C1C[C@@]3([H])C[C@@]4([H])[C@H](N(C)C)C(O)=C(C(N)=O)C([C@@]4(O)C(O)=C32)=O)CN5CCCC5
-
Synonyms
TP-434
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (30)
-
Journal Impact Factor
-
Most Recent
-
Nat Microbiol
Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains. [Abstract]2023 Mar;8(3):410-423. PMID: 36759752 -
Biomaterials
Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1/CCL5 mediated M1 macrophage polarization in melanoma. [Abstract]2024 Sep 11:314:122815. PMID: 39288620
Eravacycline purchased from MedChemExpress. Usage Cited in: Biomaterials. 2024 Sep 11:314:122815. [Abstract]
Detection of melanoma cell clone formation after (0–10 μM) ERV (Eravacycline dihydrochloride) treatment for 48 h. The results showed that ERV significantly reduced the clone formation ability of melanoma cells.
Eravacycline purchased from MedChemExpress. Usage Cited in: Biomaterials. 2024 Sep 11:314:122815. [Abstract]
The protein levels of LC3 in B16F10 and Sk-Mel-28 cells were detected using western blotting after (2–5 μM) ERV (Eravacycline dihydrochloride) treatment for 48 h.
Eravacycline purchased from MedChemExpress. Usage Cited in: Biomaterials. 2024 Sep 11:314:122815. [Abstract]
Confocal microscopy was used to detect LC3 aggregation in B16F10 and Sk-Mel-28 cells after ERV (Eravacycline dihydrochloride) (5 μM) treatment for 48 h.
Eravacycline purchased from MedChemExpress. Usage Cited in: Biomaterials. 2024 Sep 11:314:122815. [Abstract]
The protein levels of LC3 in Sk-Mel-28 cells were detected using western blotting after ERV (Eravacycline dihydrochloride) (5 μM)/CQ (25 nm)/NAC (5 mM) treatment for 48 h.
Eravacycline purchased from MedChemExpress. Usage Cited in: Biomaterials. 2024 Sep 11:314:122815. [Abstract]
The protein levels of CCL5 in B16F10 and Sk-Mel-28 cells were detected using ELISA after (5 μM) ERV (Eravacycline dihydrochloride) treatment for 48 h.
Eravacycline purchased from MedChemExpress. Usage Cited in: Biomaterials. 2024 Sep 11:314:122815. [Abstract]
In co-culture system, the mRNA levels of IL1β and Cd86 in (100 ng/mL) LPS treated-RAW264.7 cells were detected using qRT-PCR after (5 μM) ERV (Eravacycline dihydrochloride) treatment for 48 h.
Eravacycline purchased from MedChemExpress. Usage Cited in: Biomaterials. 2024 Sep 11:314:122815. [Abstract]
Flow cytometry was used to detect the proportion of MHCII+F4/80+CD11B+ cells in (100 ng/mL) LPS treated-RAW264.7 and peritoneal macrophages after (5 μM) ERV (Eravacycline dihydrochloride) treatment for 48 h.
-
Nat Struct Mol Biol
2023 Sep;30(9):1380-1392. PMID: 37550453 -
Pharmaceutics
2021 Dec 5;13(12):2085. PMID: 34959366 -
Virulence
MALDI-TOF MS for rapid detection and differentiation between Tet(X)-producers and non-Tet(X)-producing tetracycline-resistant Gram-negative bacteria. [Abstract]2022 Dec;13(1):77-88. PMID: 34951562 -
J Clin Microbiol
Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole. [Abstract]2020 Jan 28;58(2):e01603-19. PMID: 31748318 -
mBio
Cryo-EM Determination of Eravacycline-Bound Structures of the Ribosome and the Multidrug Efflux Pump AdeJ of Acinetobacter baumannii. [Abstract]2021 Jun 29;12(3):e0103121. PMID: 34044590 -
Antibiotics (Basel)
Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates. [Abstract]2022 Sep 23;11(10):1298. PMID: 36289956 -
Antimicrob Agents Chemother
Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii. [Abstract]2024 Mar 6;68(3):e0112023. PMID: 38289044 -
Antimicrob Agents Chemother
Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive Enterobacterales. [Abstract]2021 May 18;65(6):e00203-21. PMID: 33820763 -
Antimicrob Agents Chemother
In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus. [Abstract]2019 May 24;63(6). pii: e00470-19. PMID: 30962331 -
Ann Lab Med
In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis. [Abstract]2021 May 1;41(3):293-301. PMID: 33303714 -
Microbiol Spectr
The adaptive growth and mechanisms of Klebsiella pneumoniae under sucrose and glucose exposure. [Abstract]2025 Oct 16:e0160325. PMID: 41099518 -
ACS Infect Dis
2024 Dec 13;10(12):4127-4136. PMID: 39537364 -
Microbiol Spectr
Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity In Vitro. [Abstract]2023 Jun 15;11(3):e0071823. PMID: 37140428 -
Microbiol Spectr
In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria. [Abstract]2023 Feb 14;11(1):e0323822. PMID: 36475850
Eravacycline purchased from MedChemExpress. Usage Cited in: Microbiol Spectr. 2023 Feb 14;11(1):e0323822. [Abstract]
The MIC distributions of Eravacycline against 43 M. fortuitum isolates. The y axis shows the number of strains with each MIC value, with the specific numbers shown above the bars.
-
J Antimicrob Chemother
In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. [Abstract]2021 Jul 15;76(8):2071-2078. PMID: 33956969 -
J Antimicrob Chemother
Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. [Abstract]2021 Feb 11;76(3):653-658. PMID: 33258923 -
Microb Pathog
Comparison of antimicrobial efficacy of eravacycline and tigecycline against clinical isolates of Streptococcus agalactiae in China: In vitro activity, heteroresistance, and cross-resistance. [Abstract]2020 Dec;149:104502. PMID: 32947016 -
Pathology
In vitro activity of recently introduced Gram-positive-specific antimicrobial agents against Australian methicillin-resistant Staphylococcus aureus isolates. [Abstract]2026 Feb 6:S0031-3025(26)00393-4. PMID: 41760492 -
Infect Drug Resist
In vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives Against Levofloxacin-Non-Susceptible and/or Trimethoprim-Sulfamethoxazole-Resistant Stenotrophomonas maltophilia. [Abstract]2023 Sep 8:16:6005-6015. PMID: 37705512 -
Infect Drug Resist
Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study. [Abstract]2023 Apr 17:16:2271-2279. PMID: 37090037 -
J Antibiot (Tokyo)
Combined effect of eravacycline and omadacycline with other antimicrobial agents against Acinetobacter Baumannii. [Abstract]2026 May 27. PMID: 42204275 -
J Antibiot (Tokyo)
In vitro synergistic effect and mutant prevention concentration of eravacycline alone or in combination with various antibiotics against OXA-48 producing enterobacterales. [Abstract]2025 May;78(6):370-379. PMID: 40329078 -
J Antibiot (Tokyo)
In vitro activity and adaptation strategies of eravacycline in clinical Enterococcus faecium isolates from China. [Abstract]2022 Sep;75(9):498-508. PMID: 35896611 -
J Antibiot (Tokyo)
In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates. [Abstract]2019 Aug;72(8):600-604. PMID: 31028352 -
Clin Exp Pharmacol Physiol
In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria. [Abstract]2023 Jul;50(7):604-609. PMID: 37086075 -
Diagn Micr Infec Dis
In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China. [Abstract]2020 Nov;98(3):115129. PMID: 32739761 -
Cureus
2024 Dec 1;16(12):e74917. PMID: 39742159 -
Protocole
Rats[3]
Pharmacokinetic (PK) parameters are determined in Sprague−Dawley rats. Animals are fasted overnight (minimum of 12 h) and given a single oral (10 mg/kg) or IV dose (1 mg/kg) of eravacycline followed by a sampling scheme for 24 h. Plasma and dosing solution concentrations are determined by TurboIonspray LC/MSMS analysis using appropriate standard curves. PK parameters are calculated by noncompartmental analysis.
Mice[5]
Eravacycline is formulated in sterile 0.9% saline. BALB/c mice are inoculated with 0.2 mL of prepared bacterial inoculum via intravenous injection to seed the kidney. Animals are administered antibiotics (eravacycline) at 10 mL/kg i.v. via the tail vein 12 and 24 h postinfection. Then the bacterial burden is determined.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
Références
[1]. Seifert H, et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2017 Jul 10. [Content Brief]
[2]. Zhao M, et al. In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. Antimicrob Agents Chemother. 2017 Jun 27;61(7). [Content Brief]
[3]. Xiao XY, et al. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem. 2012 Jan 26;55(2):597-605. [Content Brief]
[4]. Sutcliffe JA, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. [Content Brief]
[5]. Grossman TH, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015 May;59(5):2567-71. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Eravacycline Related Classifications
HY-16980 Related Classifications
Powered by Bioz